Large-scale infectious disease testing programs have little consideration for equity : findings from a scoping review

Large-scale infectious disease testing programs have little consideration for equity : findings from a scoping review Ost K. auteur aut IRD Duquesne L. auteur aut IRD Duguay C. auteur aut IRD Traverson Lola auteur aut IRD Mathevet I. auteur aut IRD Ridde Valéry auteur aut IRD Zinszer K. auteur aut IRD text journalArticle eng text/pdf born digital access Objective: This scoping review aimed to identify how equity has been considered in large-scale infectious disease testing initiatives. Study Design and Setting: Large-scale testing interventions are instrumental for infectious disease control and a central tool for the coronavirus 19 (COVID-19) pandemic. We searched Web of Science: core collection, Embase and Medline in June 2021 and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses recommendations for scoping reviews. We critically analyzed the content of all included articles. Results: Our search resulted in 2448 studies of which 86 were included for data extraction after screening. Of the included articles, 80% reported on COVID-19 -related screening programs. None of the studies presented a formal definition of (in)equity in testing, however, 71 articles did indirectly include elements of equity through the justification of their target population. Of these 71 studies, 58% articles indirectly alluded to health equity according to the PROGRESS-Plus framework, an acronym used to identify a list of socially stratifying characteristics driving inequity in health outcomes. Conclusion: The studies included in our scoping review did not explicitly consider equity in their design or evaluation which is imperative for the success of infectious disease testing programs. specialized Scoping review COVID-19 Equity Inequity Testing programs HIV Ebola PROGRESS-Plus framework TIDieR-PHP MONDE 056 052 Journal of Clinical Epidemiology 143 30-60 2022 0895-4356 https://www.documentation.ird.fr/hor/fdi:010083948 10.1016/j.jclinepi.2021.11.030 0895-4356 [F B010083948] https://www.documentation.ird.fr/hor/fdi:010083948 https://www.documentation.ird.fr/intranet/publi/2022-02/010083948.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2022-02-04 2025-02-24 fdi:010083948 fre